Hans Rommelspacher

AudioCure Pharma GmbH provides preclinical research and clinical development of novel pharmacotherapies to treat disorders of the inner ear. It engages in the clinical development of drug candidates in neurodegenerative disease indications. The firm's offer medicine for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear. The company was founded by Hans Rommelspacher in 2010 and is headquartered in Berlin, Germany.

AudioCure Pharma GmbH provides preclinical research and clinical development of novel pharmacotherapies to treat disorders of the inner ear. It engages in the clinical development of drug candidates in neurodegenerative disease indications. The firm's offer medicine for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear. The company was founded by Hans Rommelspacher in 2010 and is headquartered in Berlin, Germany.

AudioCure Pharma GmbH provides preclinical research and clinical development of novel pharmacotherapies to treat disorders of the inner ear. It engages in the clinical development of drug candidates in neurodegenerative disease indications. The firm's offer medicine for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear. The company was founded by Hans Rommelspacher in 2010 and is headquartered in Berlin, Germany.